TriNetX buffs Sanofi's digital trials and other digital health deals

By Dave Muoio
10:42 am

Sanofi has found yet another partner to help digitize its clinical trial processes. In a statement, TriNetX announced that it will be assisting the pharmaceutical company by using patient EHRs to optimize recruitment, streamline trial investigators’ workflows, and otherwise impact the design of investigational drug trials. Sanofi has made similar arrangements to bolster its clinical trials with Science 37 and Evidation in March and July of last year, respectively.

“Clinical trials are becoming ever more complex, and anything we can do to reduce the time and cost of a trial means therapies can be evaluated more rapidly and reach people faster,” Lionel Bascles, global head of clinical sciences and operations at Sanofi, said in a statement. “Working with companies like TriNetX is an important way to do that, by bringing both technology and knowledge to Sanofi’s work.”

Florida Hospital New Smyrna has launched a tele-ICU service powered by telemedicine provider Advanced ICU Care, the latter recently announced. The new program will offer patients 24-7 care using a secure data stream of patient information and two-way audio-video tools, and is the latest partnership between Advanced ICU Care and the Adventist Health System.

“Providing our ICU patients with the highest quality of care is a top priority for Florida Hospital New Smyrna,” Ken Mattison, CEO of Florida Hospital New Smyrna, said in a statement. “Expanded access to intensivist-led care through Advanced ICU Care’s tele-ICU service complements our efforts to provide our patients exceptional critical care and deliver access to the gold standard of 24-7 intensivist oversight to our community.”

Managed care company Magellan Health has announced a pilot program offering PEAR Therapeutics’ prescription digital therapeutic, reSET. The program will enroll 250 patients with substance abuse disorder for a 12-week course of the therapy, with a series of publications covering the results and observations planned following its conclusion.

“This prescription digital therapeutic alternative offers physicians and members an evidence-based, non-drug treatment option, which is critical when you consider our nation’s current challenges with substance use,” Dr. Maria Lopes, chief medical officer at Magellan RxManagement, said in a statement. “Industry collaborations like this allow us to rethink the way treatment is delivered and offer practical solutions to meet the complex needs we face today.”

1Vision, a government-focused IT firm, has partnered with AMC Health to fulfill a contract from the Departments of Veterans Affairs delivering home telehealth to US veterans. AMC Health’s CareConsole platform will allow veterans to automatically transmit vital signs or condition-specific information through Bluetooth-enabled devices, while alerting care coordinators to concerning health issues and trends.

“We are honored that AMC Health has been selected to help empower veterans to take a more active role managing their health and improving the quality of lives,” Nesim Bildirici, CEO and president of AMC Health, said in a statement. “As the exclusive telehealth provider for 1Vision, we are committed to extending our expertise to help expand medical services to veterans through telehealth.”

The Renown Institute for Health Innovation — a research collaboration between the Renown Health network and the Desert Research Institute — will be including Helix’s DNA sequencing products for the second phase of its Healthy Nevada Project. The program will offer 40,000 Nevadans free information on their personal traits and ancestry as well as a account at no cost, should they agree to participate in the research.

“From the beginning, our focus with the Healthy Nevada Project has been on delivering personalized health data to our communities that will ultimately drive positive change for our state,” Dr. Anthony Slonim, president and CEO of Renown Health and president of the Renown Institute for Health Innovation, said in a statement. “We are very excited about the opportunities the next phase of this groundbreaking study will offer. Community participants will be able to gain deeper, actionable insights into their DNA data, while our research teams gain unprecedented access to the largest clinical exome sequencing facility in the world.”


Mount Sinai Health Partners has entered a multi-year arrangement with Health Fidelity to employ the latter’s natural language processing technology to assess the risk of more than 300,000 members. According to a statement, Mount Sinai made the deal after Health Fidelity ran an initial demonstrative risk assessment outlining opportunities to optimize risk. Moving forward, the network will also be looking at ways that using the tool could be used to expand their participation in value-based care programs.

“We needed to develop a holistic risk adjustment strategy supported with the right tools as we continue our growth in this market,” Michael Berger, VP of population health informatics and data science at Mount Sinai Health Partners, said in a statement. “One of the areas that Health Fidelity has been tremendously valuable is in helping us understand and quantify opportunities for success in our risk adjustment program, including how we can leverage technology to gain further improvements.”


The latest news in digital health delivered daily to your inbox.

Thank you for subscribing!
Error! Something went wrong!